[EN] IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF<br/>[FR] COMPOSÉS À BASE D'IMIDAZO [1, 2-B] PYRIDAZINE, COMPOSITIONS LES COMPRENANT ET UTILISATIONS DE CEUX-CI
申请人:LEXICON PHARMACEUTICALS INC
公开号:WO2013134219A1
公开(公告)日:2013-09-12
Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
Enabling Reductive C–N Cross-Coupling of Nitroalkanes and Boronic Acids by Steric Design of P(III)/P(V)═O Catalysts
作者:Gen Li、Yuzuru Kanda、Seung Youn Hong、Alexander T. Radosevich
DOI:10.1021/jacs.2c01487
日期:2022.5.11
bond-forming reductive coupling of nitroalkanes with arylboronicacids and esters is reported. The method shows excellent chemoselectivity for the nitro/boronicacid substrate pair, allowing the synthesis of N-(hetero)arylamines rich in functionalization. The identification of a sterically reduced phosphetane catalyst capable of productive coupling in the P(III)/P(V)═O redox manifold is the key enabling development
Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
申请人:Bi Yingzhi
公开号:US08969565B2
公开(公告)日:2015-03-03
Imidazo[1,2-b]pyridazine-based compounds of the formula:
are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
申请人:BI Yingzhi
公开号:US20130245021A1
公开(公告)日:2013-09-19
Imidazo[1,2-b]pyridazine-based compounds of the formula:
are disclosed, wherein R
1
, R
2
and R
3
are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
This investigation demonstrates that the appropriate positioning of a customized boronicacidprobe into a sialic acid binding epitope leverages a selective and potent binder of sialyl-glycan. Such synergistic peptideprobe is promising in clinical oncology for diagnosis.